Overview
- GRAIL faces the FDA’s Molecular and Clinical Genetics advisory panel on Wednesday, Sept. 23, which will review the company’s premarket approval application for the Galleri multi‑cancer screening blood test.
- FDA staff reviewers told advisers in briefing documents that they had no major outstanding concerns about Galleri’s analytical performance, accuracy or safety.
- Clinical evidence is mixed: a large U.K. randomized trial of roughly 142,000 people found Galleri detected more cancers and produced a 16% increase in early‑stage diagnoses for 12 deadly cancers, while a pivotal three‑year analysis later reported it did not meet its primary endpoint for reducing late‑stage diagnoses.
- Investors have driven sharp share gains for GRAIL ahead of the non‑binding advisory vote, reflecting market bets that the panel could boost approval odds even though the FDA will still make the final decision.
- If approved, Galleri would move beyond its current CLIA lab‑developed test status and likely reach wider clinical use with insurer and Medicare coverage, which could expand access but also raise questions about follow‑up testing, false positives and how to measure real patient benefit.